Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 30/2026 July 26, 2026
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026
Olaparib’s Effectiveness Duration in Prostate Cancer Treatment
/in Post-hoc/by MaxFDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxNew Hope for Castration-Resistant Prostate Cancer: Targeting EZH2
/in Preclinical Research/by MaxPhase III Trial for Metastatic Castration-Resistant Prostate Cancer of an EZH2 inhibitor
/in Clinical Trial, Metastatic, Phase 3/by MaxAMPLITUDE phase 3 Study for Metastatic Castration-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 trial for localized prostate cancer
/in Localized/by MaxPersonalized Treatment for Advanced Prostate Cancer: The Power of Multi-Tracer PET Imaging
/in Preclinical Research/by MaxCTT2274: A Potential Game-Changer for Metastatic Prostate Cancer Treatment…start hating the word “potential”
/in Preclinical Research/by Max